annually. 1 Articular cartilage is a specialised tissue for load distribution across low-friction articulating surfaces. Its coefficient of friction is extraordinarily low, being 0.002 to 0.04. By comparison, the value for steel-on-steel is 0.6 and for ice-on-ice at 0ºC it is 0.01 to 0.1. The underlying mechanism of this low coefficient of friction remains unknown. 2 Physiologically, articular cartilage is mostly an isolated tissue, being devoid of blood vessels, lymphatic channels and neurological innervation. It has just one cell type-the chondrocyte, and its cellular density is less than that of any other tissue at <10% (Fig. 1 ). 3 Chondrocytes are surrounded by a pericellular matrix consisting of collagen VI and are embedded in lacunae within the matrix. They are not very mobile and unable to migrate to damaged regions to synthesise a repair tissue. This means that cartilage is entirely dependent on nutrients from the synovial fluid.
The organic matrix is composed of a dense network of fine collagen fibrils that are meshed in a concentrated solution of proteoglycans. Collagen fibrils and proteoglycans are capable of forming structural networks of considerable strength, and thus serve as the structural components of the tissue which support the internal mechanical stresses resulting from loading. In normal articular cartilage, the collagen content is 15 to 22% and the proteoglycan content is 4 to 7% by wet weight; the remaining 60 to 85% is water, glycoproteins, lipids, inorganic salts, and small amounts of other matrix proteins. The amount of water depends on the layer within the cartilage (Fig. 2) . The surface layer is up to 80% water by volume and represents 10 to 20% of the total thickness. It contains densely packed fibres which are arranged randomly in planes parallel to the articular surface, indicating that the primary function of this zone may be to resist shearing stresses. The middle layer represents 40 to 60% of the total thickness, and the fibres are randomly arranged and farther apart compared to those in the surface layer. The deep layer represents 30% of the total thickness and consists of larger radially oriented fibre bundles, some of which cross the interface between articular and calcified cartilage and lead into the subchondral bone. Subchondral bone is a dense layer of stiff bone (around 1 mm in thickness) located between cartilage and underlying bone and consists of collagen fibres and a mineralised matrix of calcium phosphate.
OSTEOCHONDRAL DEFECTS
Osteochondral defects can be found in young atheletes following an acute injury and in patients with osteochondritis dessicans. 4 They are part of the spectrum of presentations in degenerative joints. For treatment, the underlying cause should be considered.
Injuries of the articular cartilage that do not penetrate the subchondral bone (partial thickness) do not heal and usually progress to the degeneration of the articular surface. Injuries that penetrate the subchondral bone can undergo repair through the formation of fibrocartilage. Although fibrocartilage can refill and cover the defects, its structure is inferior to the original articular cartilage. Although fibrocartilage is adequate to resist a certain amount of tensile stress, hyaline cartilage is more complex and highly organised and can resist long-term multi-axial loading and shearing forces.
NON-SURGICAL TREATMENT
Non-surgical treatments are used for arthritic joints rather than isolated osteochondral defects. Physiotherapy is the most common option and its beneficial effects are evidence-based. 5 It enables greater pain relief and functional improvement than in patients having no physiotherapy. Nonetheless, it provides symptomatic relief only, rather than treatment for the underlying disease.
Glucosamine and chondroitin sulphate are commercially available, non-prescribed medications for osteoarthritis. Both are natural products found in the composition of hyaline cartilage. Some studies report favourable symptomatic benefits and disease limitation, but none is without bias and other flaws. 6, 7 A meta-analysis suggested such studies exhibited significant biases, but nonetheless an appreciable level of efficacy was probable. 8 The Cochrane review in 2005 concluded that there was no evidence for pain relief, and functional improvement was questionable and not standardised.
Viscosupplementation is another non-surgical option for arthritic joints. It refers to the intraarticular injection of hyaluronic acid, which is a major component of synovial fluid. It was originally used in veterinary medicine for the treatment of equine arthritis. 9,10 Medium-term pain relief can be achieved in humans. 11 Evidence is emerging in support of a disease-modification role through chondrogenesis and other mechanisms at the molecular level. 12
SURGICAL TREATMENT
As osteochondral defects do not repair and the joints go on to become arthritic, surgical treatments become necessary. 13 The future of orthopaedics must focus on joint preservation. The prevalence of chondral defects in all knee arthroscopies is 5 to 7%. 14, 15 Patients younger than 40 years with one or few small Outerbridge grade IV defects are suitable candidates for osteochondral repair/regeneration. The goals are to improve joint articulation by restoring the joint surface to its original condition as far as possible and prevent further cartilage deterioration. To ensure positive outcomes, patients must be selected with great care based on aetiology, patient characteristics, as well as the location, size, and depth of the lesions.
The first-line options are marrow-stimulating techniques such as Pridie drilling, 16 abrasion arthroplasty, 17 and microfracture. 18 The advantages of the latter over drilling and abrasion are the avoidance of thermal injury and the preservation of the subchondral plate, respectively. All these techniques promote bleeding from the subchondral bone and create vascular communications to the bone marrow from which pluripotent mesenchymal stem cells are released. Ideally, these stem cells then differentiate along chondral cell-line to form cartilage, under the influence of motion, loading and other factors. This has been shown to occur, but the defect fills with fibrocartilage rather than hyaline cartilage. Furthermore, the defect does not interdigitate with the surrounding articular cartilage, and remains an area of weakness. 19 Although these techniques are accepted as beneficial and have a limited lifespan for small lesions, their clinical results are variable and trials are non-standardised. Results are superior if postoperative protected weight-bearing and range of motion exercises are adopted. 20 Up to 90% of patients can have an improved knee function score, and benefits may last up to one year. Many patients then experience deterioration again, especially athletes. 21 Despite its limitations, microfracture should be considered because it is simple, does not cause major morbidity or preclude the use of any other cartilageregeneration technique.
Larger defects may be more effectively treated with a restorative option such as mosaicplasty using either autografts or allografts. Mosaicplasty remains the most effective surgical technique for reconstructing the original height and shape of articulating surface in focal osteochondral defects. It involves composite autologous material that contains all the necessary ingredients: hyaline articular cartilage, intact tidemark, and a firm bone carrier (Fig. 3 ). For this procedure, cartilage plugs (bone with cartilage covering) are harvested from healthy, nonweight bearing areas of the joint and transplanted to the defective area. It is based on sound biomechanical principles and yields satisfactory results. In a study of 1037 patients over the course of 15 years, 789 implantations were on the femoral condyles, 147 in the patellofemoral joint, and 98 on talar domes. 22 After <3 years of follow-up, good-to-excellent results were achieved in 92% of femoral condylar mosaicplasties, 74% of patellar and/or trochlear mosaicplasties, and 93% of talar procedures. 22 Moderate-to-severe donorsite disturbances were present in 3% of the patients; good gliding surfaces, histologically proven survival of the transplanted hyaline cartilage and acceptable fibrocartilage cover of the donor sites were found in 81 of the 98 arthroscopies. 22 Of 113 patients with 6 years of follow-up, 91% yielded good-to-excellent results. 22 Restoration of a perfectly smooth articular surface is necessary, but the donor-site contours usually do not match the defect site, and incongruity of even 1 mm may lead to early wear. 23 In addition, the limited availability of autografts limits treatment to small focal chondral defects.
Osteochondral allografts have better availability (as cartilage is harvested from deceased donors) and enable treatment of larger lesions. In 60 patients with implanted femoral condyle grafts, the 10-year graft survival rate was 85% and the mean functional knee score was 83%. 24 However, the condition of the graft is optimal immediately after harvesting. It cannot be implanted before it has been screened for disease, yet it cannot be frozen, as cryopreservation kills chondrocytes. Within about 30 days, the graft must be harvested, screened, and implanted to avoid becoming non-viable. The entire process requires tight protocols and sustainable supply and demand, which can only be achieved in large specialist centres. Regarding the immunological response to the graft, increased HLA antibodies and corresponding poor graft appearance have been reported. 25 In autologous chondrocyte implantation (ACI), cartilage is taken from a low-contact area of the bone; chondrocytes are then harvested and cultured in vitro; the fresh chondrocytes are then injected into the defective area using a periosteal patch in order to aid cellular adhesion and fill in the defect. 26 Essentially this creates a bioactive-chamber and results in the development of hyaline-like cartilage 26 and thus repairs the defect (Fig. 4) . The medium-to-long-term arthroscopic, histological and clinical outcomes of the first 101 patients were promising. 27 In patients with isolated femoral lesions, 92% achieved goodto-excellent clinical results. In patients with multiple lesions this figure fell to 67%. Hyaline-like cartilage was present in 66% of biopsies and correlated with good clinical results. Periosteal hypertrophy was present in 25% of patients; one third of whom were symptomatic and underwent arthroscopic debridement. In the correct patient and performed by an experienced surgeon, ACI is advocated as the most successful procedure for treatment of defects >2 cm 2 , even at 9-year follow-up. 27 Nonetheless, chondrocytes for ACI are obtained from a biopsy taken from a minor-load bearing area of the same joint, resulting in additional injury to the joint surface. This possibly increases the risk of developing osteoarthritis, particularly in genetically predisposed individuals. Moreover, indications for this procedure may extend to joints with early osteoarthritis, but the availability of healthy cartilage for biopsy may be a limiting factor. 28 The expansion of mature chondrocytes in vitro to obtain clinically sufficient numbers of cells is also a restriction; such expansion in a monolayer culture is known to induce de-differentiation of the chondrocyte into a more fibroblast-like cell.
NEW DEVELOPMENT
The use of the chondrocyte directly at the defective site is the future for ACI. The periosteal patch requires meticulous and time-consuming implantation; in some patients it may lead to hypertrophy. Thus, instead of using periosteum to hold the chondrocytes in place, the use of a fibrin/thrombin mixture has yielded favourable results in a horse model. 29 Different materials have also been used, such as collagen 30 and a hyaluronic acid derivative. 31 These techniques are referred to as matrix-induced ACI. Their longterm results have not yet been reported, but initial arthroscopic, histological and clinical results appear to be promising. 32, 33 Culturing chondrocytes is a time-consuming process; the use of a different cell-type rather than autologous chondrocyte is therefore advocated. The use of minced allogeneic whole cartilage 34 is claimed to provide chondrogenesis potential, without the need for chondrocyte culture ex vivo. Mesenchymal stem cells (MSCs) in various types of scaffold with various additional growth mediators have also been used in animals. 35 MSCs have also been cultured ex vivo to provide whole sections of hyaline cartilage for subsequent implantation into osteochondral defects. 36 Autologous matrix-induced chondrogenesis (AMIC) is a technique that makes use of the regenerative capacity of MSCs within the native bone marrow. It involves placing a collagen matrix over the defect immediately following microfracture. This cover then traps the first few millilitres of bone Surgical options are extensive. Decision on the most suitable option requires consideration of patient characteristics and the lesion's location, size and depth. In general, a microfracture technique is indicated for lesions of up to 2 cm 2 , 20 mosaicplasty for lesions >2 cm 2 , 22 and fresh allografts for extremely large defects. ACI, matrix-induced MACI, and AMIC have been used for lesions up to 12 cm 2 . 27
OUTCOME ASSESSMENT
A joint that remains healthy, a stable edge after debridement, and restoration of a congruent articulating surface are intra-operative predictors of a favourable outcome. 15, 18, 22 Postoperative assessment tools are limited. The most accurate way is to undertake repeated arthroscopy and biopsies of the new cartilage. However, this compromises the benefits of the initial procedure and is unethical. Noninvasive radiological means are therefore advocated. Magnetic resonance imaging is useful for identifying cartilage defects, but cannot differentiate hyaline cartilage from fibrocartilage. Magnetic resonance observation of cartilage repair tissue (MOCART) is an adaptation of MRI to specifically look at the quality of repaired cartilage. 37 Although it does not provide a histological diagnosis, it gives a clear picture of outcome for comparison and quantitative evaluation. The MOCART score is the most reliable means and has potential for further development. 38 
COST
The cost of osteochondral-defect treatment is difficult to quantify. Most surgical options require specific training, although specialist training provides only the technical know-how. An efficiently coordinated and well-funded multidisciplinary team is required for allografting or cellular-based techniques. Isolated surgical costs from an established tertiary referral centre in 2005 were approximately £7000 for an ACI and £4000 for a mosaicplasty procedure. 39 Microfracture is the technique commonly used by non-specialist orthopaedic surgeons and is relatively inexpensive.
CONCLUSIONS
Cartilage regeneration surgeries can have unpredictable results. With the increasing prevalence of osteochondral defects, research and development should be focused on developing standardised cartilage repair techniques. At present, treatment options remain limited and long-term outcomes uncertain. Overall, the larger the lesion, the more load is distributed across it, and the less favourable the treatment outcome. Further randomised controlled trials on the various techniques of cartilage regeneration are needed to determinate the choice of treatment for any given defect.
